(Q35850483)

10 August 2017

1 reference

title

Drotrecogin alfa: a role in emergency department treatment of severe sepsis? (English)

1 reference

10 August 2017

0 references

1 reference

Adam M McLeay

1

1 reference

10 August 2017

1 August 2004

1 reference

Emergency Medicine Australasia

10 August 2017

1 reference

10 August 2017

16

1 reference

10 August 2017

4

1 reference

10 August 2017

324-335

1 reference

Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation

10 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

21 January 2018

The protein C pathway

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Activation of endothelial cell protease activated receptor 1 by the protein C pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Vascular-bed--specific hemostasis and hypercoagulable states

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Management of patients with severe sepsis, treated by drotrecogin alfa (activated).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Modulation of endothelial cell hemostatic properties by tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Activated protein C versus protein C in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Low levels of protein C are associated with poor outcome in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

An update on clinical and basic aspects of the protein C anticoagulant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Protein C activation following coronary artery occlusion in the in situ porcine heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Risks and benefits of activated protein C treatment for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Assessing the use of activated protein C in the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Recombinant human activated protein C for the treatment of severe sepsis: is there a role in pediatrics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Recombinant activated protein C in pediatric sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Early goal-directed therapy in the treatment of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Intra-observer variability in APACHE II scoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Inter-observer variability in APACHE II scoring: effect of strict guidelines and training.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Mortality in Emergency Department Sepsis (MEDS) score: a prospectively derived and validated clinical prediction rule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

Dysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-6723.2004.00630.X

10.1111/J.1742-6723.2004.00630.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15283720